EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Attenuated Dose Dasatinib in Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase Patients in India.

Rayaz Ahmed, Reema Singh, Jyotsna Kapoor, Pritish Chandra Patra, Narendra Agrawal, Dinesh Bhurani, Rohan Halder

Clinical Lymphoma Myeloma and Leukemia · 2023-02 · 23 (2) · e71-e77

DOI: 10.1016/j.clml.2022.11.006 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2023-02. Verfasst von Rayaz Ahmed und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Bone Marrow Transplant Unit, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India. Hauptthemen laut MEDLINE: Antineoplastic Agents, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Rajiv Gandhi Cancer Institute and Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: BCR-ABL Tyrosine kinase inhibitors (TKI's) are most successful of targeted therapies and are currently considered the cornerstone in the management of patients with chronic myeloid leukemia (CML). A recent study reported excellent outcomes of Dasatinib 50mg with better sustained response. Therefore, we aim to evaluate the molecular responses and safety of upfront Dasatinib 50mg in Indian CML-Chronic Phase patients. METHODS: It was an observational single-centre study. CML-CP patients started on Dasatinib 50mg daily were offered to participate in this study. Data of imatinib was collected retrospectively as a comparator group. RESULTS: Between June 2020 to Feb 2022, fifty patients were included in the dasatinib 50mg once daily group. Median age was 40 yrs. ranging from (19 to73) years. At a median follow up of 9.2 months, 49 patients completed three months treatment, out of which 48 patients were evaluated as one patient stopped medication after a month due to financial constraints. The response rate at three months for dasatinib 50mg daily and Imatinib were 68.75% and 69.7% respectively. At 12 months, 68% and 66.6% patients achieved major molecular response [MMR] in dasatinib 50mg and imatinib groups respectively. CONCLUSION: In conclusion, low dose dasatinib is safe and effective as an upfront therapy in CML-CP. Early molecular response [EMR] rates were comparable in low dose dasatinib and imatinib arm but deep molecular responses were significantly higher in low dose dasatinib arm. Dasatinib, taken daily at a dose of 50mg, may offer a new, alternative choice as generic versions are available now for frontline therapy in CML-CP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Chronic-PhaseAdultHumansDasatinibImatinib MesylateIndiaProtein Kinase InhibitorsRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

Lower dose dasatinib

Substanzen

Antineoplastic AgentsDasatinibImatinib MesylateProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Hematology and Bone Marrow Transplant Unit, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India.
  • Department of Hematology and Bone Marrow Transplant Unit, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India. Electronic address: reemasinghcr@gmail.com.

Förderung

  • Rajiv Gandhi Cancer Institute and Research Centre

Zitieren

APA

Ahmed, R., Singh, R., Kapoor, J., Chandra Patra, P., Agrawal, N., Bhurani, D., & Halder, R. (2023). Attenuated Dose Dasatinib in Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase Patients in India. Clinical Lymphoma Myeloma and Leukemia, 23(2), e71-e77. https://doi.org/10.1016/j.clml.2022.11.006

Vancouver

Ahmed R, Singh R, Kapoor J, Chandra Patra P, Agrawal N, Bhurani D, et al. Attenuated Dose Dasatinib in Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase Patients in India. Clinical Lymphoma Myeloma and Leukemia. 2023;23(2):e71-e77. doi:10.1016/j.clml.2022.11.006

BibTeX
@article{Ahmed2023,
  author = {Ahmed, Rayaz and Singh, Reema and Kapoor, Jyotsna and Chandra Patra, Pritish and Agrawal, Narendra and Bhurani, Dinesh and Halder, Rohan},
  title = {Attenuated Dose Dasatinib in Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase Patients in India},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2023},
  volume = {23},
  number = {2},
  pages = {e71--e77},
  doi = {10.1016/j.clml.2022.11.006}
}
Kostenlos starten →